Krieger K, Heine J, Dumont P, Hellmann K
Bayer HealthCare AG, Animal Health, R&D Parasiticides, 51368, Leverkusen, Germany.
Datavet S.A., 48 impasse des Eglantiers, 34980, Saint Clement de Riviere, France.
Parasitol Res. 2005 Oct;97 Suppl 1:S81-S88. doi: 10.1007/s00436-005-1449-9.
Efficacy and safety of treatment with imidacloprid 10%+moxidectin 2.5% spot-on (Advocate, Advantage multi; Bayer AG, Leverkusen, Germany) were tested in dogs naturally infested with Sarcoptes scabiei or Otodectes cynotis in a multi-centre, controlled, randomized, blinded field study conducted in France, Germany, Albania and the UK. The study was performed according to a non-inferiority design to demonstrate that the efficacy of imidacloprid/moxidectin spot-on was not inferior to that of a control product containing selamectin (Stronghold spot-on; Pfizer). All Sarcoptes-infested dogs were topically treated twice (days 0 and 28) with the dosage recommended by the respective manufacturer (27 dogs with imidacloprid/moxidectin, 26 with selamectin). All Otodectes-infested dogs were treated on day 0 (35 dogs with imidacloprid/moxidectin, 34 with selamectin), and only those still positive on day 28 received a second treatment. Parasitological cure rate in Sarcoptes-infested dogs was 100% for both treatments, while parasitological cures rates in the Otodectes-infested dogs at day 28 and day 56 were 68.6 and 85.7% with imidacloprid/moxidectin, and 64.7 and 88.2% with Stronghold. Non-inferiority of Advocate was confirmed statistically. Clinical assessment of skin lesion scores at day 56 showed that with either product >96% of the dogs treated against sarcoptic mange were improved or cured, the difference between the groups being non-significant. On the basis of a final clinical assessment of lesion scores, 80% of the dogs treated with imidacloprid/moxidectin against otoacariosis and 85.3% of those treated with selamectin were rated cured or improved. Only three mild, possibly drug-related adverse reactions were observed among alI treated animals (two in the imidacloprid/moxidectin group, one in the selamectin group). It is concluded that imidacloprid/moxidectin spot-on is an effective and safe treatment for sarcoptic mange and otoacariosis in the dog.
在法国、德国、阿尔巴尼亚和英国进行的一项多中心、对照、随机、双盲现场研究中,对10%吡虫啉+2.5%莫昔克丁滴剂(Advocate,Advantage multi;德国勒沃库森拜耳公司)治疗自然感染疥螨或耳螨的犬的疗效和安全性进行了测试。该研究采用非劣效性设计,以证明吡虫啉/莫昔克丁滴剂的疗效不低于含塞拉菌素的对照产品(Stronghold滴剂;辉瑞公司)。所有感染疥螨的犬均按照各自制造商推荐的剂量(27只使用吡虫啉/莫昔克丁,26只使用塞拉菌素)进行两次局部治疗(第0天和第28天)。所有感染耳螨的犬在第0天接受治疗(35只使用吡虫啉/莫昔克丁,34只使用塞拉菌素),只有那些在第28天仍呈阳性的犬接受第二次治疗。两种治疗方法对感染疥螨的犬的寄生虫学治愈率均为100%,而在第28天和第56天,感染耳螨的犬使用吡虫啉/莫昔克丁的寄生虫学治愈率分别为68.6%和85.7%,使用Stronghold的治愈率分别为64.7%和88.2%。统计学上证实了Advocate的非劣效性。第56天对皮肤病变评分的临床评估表明,使用任一产品治疗疥螨病的犬中,>96%的犬病情得到改善或治愈,两组之间的差异无统计学意义。根据对病变评分的最终临床评估,使用吡虫啉/莫昔克丁治疗耳螨病的犬中80%被评定为治愈或改善,使用塞拉菌素治疗的犬中85.3%被评定为治愈或改善。在所有接受治疗的动物中,仅观察到3例轻度、可能与药物相关的不良反应(吡虫啉/莫昔克丁组2例,塞拉菌素组1例)。得出的结论是,吡虫啉/莫昔克丁滴剂是治疗犬疥螨病和耳螨病的一种有效且安全的方法。